Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06629779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Name: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — clinical trial record (NCT06629779)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorPfizer

Started2024-10-22

View on ClinicalTrials.gov ↗

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Amendment history 1 change detected by DataLookout

2026-07-30

Trial sites reduced: 240 → 237 locations

Trial Details

NCT Number	NCT06629779
Lead Sponsor	Pfizer
Conditions	Metastatic Castration-Resistant Prostate Cancer
Enrollment	900 participants
Start Date	2024-10-22
Primary Completion	2026-12-02 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-24